Schoenberg Mark's Insider Trades & SAST Disclosures
Schoenberg Mark's most recent trade in UroGen Pharma Ltd was a trade of 20,000 Restricted Stock Units done . Disclosure was reported to the exchange on Jan. 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Schoenberg Mark.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 148,999 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 150,436 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 3,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,896 | 147,103 (0%) | 0% | 11.1 | 21,121 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,896 | 148,540 (0%) | 0% | 11.1 | 21,121 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,334 | 146,425 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,334 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 759 | 145,666 (0%) | 0% | 11.1 | 8,455 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 1,666 | 145,950 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 1,666 | 3,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 09 Sep 2024 | 859 | 145,091 (0%) | 0% | 13.1 | 11,236 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,000 | 20,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,000 | 149,437 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 10 Jun 2024 | 5,153 | 144,284 (0%) | 0% | 13.1 | 67,401 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.05 per share. | 18 Mar 2024 | 12,000 | 139,437 (0%) | 0% | 14.1 | 168,600 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 3,333 | 153,331 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 2,000 | 150,560 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 2,000 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 1,894 | 151,437 (0%) | 0% | 15.7 | 29,812 | Ordinary Shares |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 1,894 | 151,437 (0%) | 0% | 15.8 | 29,887 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 1,333 | 150,756 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 1,333 | 1,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Schoenberg Mark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 1,137 | 149,423 (0%) | 0% | 15.7 | 17,896 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 1,137 | 149,423 (0%) | 0% | 15.8 | 17,942 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 758 | 149,998 (0%) | 0% | 15.7 | 11,931 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 758 | 149,998 (0%) | 0% | 15.8 | 11,961 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 2,000 | 148,879 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 1,333 | 2,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 1,333 | 149,221 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 991 | 147,888 (0%) | 0% | 10.1 | 10,029 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 661 | 148,560 (0%) | 0% | 10.1 | 6,689 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 500 | 147,127 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 500 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.12 per share. | 31 Jan 2023 | 248 | 146,879 (0%) | 0% | 10.1 | 2,510 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 20 Jan 2023 | 122,677 | 146,627 (0%) | 0% | 5 | 613,385 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2023 | 122,677 | 0 | - | - | Employee Stock Option (right to buy) | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 500 | 24,208 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 500 | 500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.85 per share. | 31 Oct 2022 | 258 | 23,950 (0%) | 0% | 11.8 | 3,057 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2022 | 500 | 1,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2022 | 500 | 23,967 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.81 per share. | 31 Jul 2022 | 259 | 23,708 (0%) | 0% | 7.8 | 2,023 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 500 | 23,721 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 500 | 1,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.62 per share. | 30 Apr 2022 | 254 | 23,467 (0%) | 0% | 6.6 | 1,681 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 12,064 | 12,064 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,000 | 4,000 | - | - | Restricted Stock | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,000 | 24,320 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 1,099 | 23,221 (0%) | 0% | 7.6 | 8,330 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 500 | 22,595 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 500 | 2,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.58 per share. | 31 Jan 2022 | 275 | 22,320 (0%) | 0% | 7.6 | 2,085 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2022 | 209 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2022 | 209 | 22,206 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.09 per share. | 26 Jan 2022 | 111 | 22,095 (0%) | 0% | 8.1 | 898 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 13.10 per share. | 18 Nov 2021 | 160 | 21,997 (0%) | 0% | 13.1 | 2,096 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2021 | 500 | 2,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2021 | 500 | 22,095 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.16 per share. | 31 Oct 2021 | 258 | 21,837 (0%) | 0% | 17.2 | 4,427 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 208 | 209 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 208 | 21,702 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.32 per share. | 26 Oct 2021 | 107 | 21,595 (0%) | 0% | 16.3 | 1,746 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2021 | 500 | 21,737 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2021 | 500 | 3,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.64 per share. | 31 Jul 2021 | 243 | 21,494 (0%) | 0% | 15.6 | 3,801 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 208 | 20,924 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 208 | 417 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.30 per share. | 26 Jul 2021 | 103 | 20,821 (0%) | 0% | 15.3 | 1,576 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 500 | 21,375 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 500 | 3,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Apr 2021 | 243 | 21,132 (0%) | 0% | 20 | 4,860 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 209 | 20,964 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 209 | 625 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.63 per share. | 26 Apr 2021 | 89 | 20,875 (0%) | 0% | 19.6 | 1,747 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 2,000 | 21,831 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.07 per share. | 02 Feb 2021 | 1,076 | 20,755 (0%) | 0% | 22.1 | 23,747 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 208 | 834 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 208 | 19,931 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.12 per share. | 26 Jan 2021 | 100 | 19,831 (0%) | 0% | 22.1 | 2,212 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 1,042 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 1,042 | 20,385 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.85 per share. | 04 Dec 2020 | 662 | 19,723 (0%) | 0% | 19.9 | 13,141 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2020 | 208 | 1,042 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2020 | 208 | 19,444 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.95 per share. | 26 Oct 2020 | 101 | 19,343 (0%) | 0% | 21.0 | 2,116 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 1,041 | 1,042 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 1,041 | 19,584 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 04 Sep 2020 | 348 | 19,236 (0%) | 0% | 20.2 | 7,030 | Ordinary Shares |
| UroGen Pharma Ltd | Mark Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 209 | 18,613 (0%) | 0% | - | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges